• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Botulinum Toxin — The Dose-Response Relationship and What It Means for Clinical Practice

Does having a bigger dose of Botox make it last longer?

medicine has a relationship, the that the biological effect of a drug varies with the amount . In most of medicine, this is to clinical decision-making: too little no meaningful effect, too much toxicity, and the window between the two is where good practice operates.

toxin is no different. And yet the in Botox is rarely discussed with the rigour it deserves. This is partly because the of are commercial rather than immediately harmful, and partly the relationship between dose, effect, and is more than a simple linear model would suggest. it changes how the should be planned, delivered, and followed up.

The most clinically important aspect of the botulinum toxin dose-response curve is the of a threshold below which the effect is . toxin acts by blocking the release of acetylcholine at the junction, but the has a considerable safety margin.

Under normal physiological conditions, a motor nerve terminal releases considerably more acetylcholine than is needed to trigger muscle contraction. This redundancy means that of release, produced by a sub-therapeutic dose of toxin, may produce no effect at all, because the remaining to release to contraction.

The practical implication is that there is a minimum effective dose below which the simply does not respond and that the dose to cross that threshold varies considerably between patients on muscle mass, muscle strength, and variation in neuromuscular junction . A who applies a fixed low dose to every patient without clinical is not some . They are not treating some patients at all.

Above the threshold, the dose and duration is well . Patients can expect to last three months or more, but often as many as four to five months depending on the facial area, dose, and . toxin treatments may duration of effect or potentiate the effect.

The dose-duration has been directly in trials with compelling results. A phase II controlled trial found that 40 units of prabotulinumtoxinA, twice the dose, produced a median duration of effect of 183 days, compared to 149 days for the standard 20 unit dose. In this pilot study, the higher dose was observed to be safe and produced a duration of approximately six months.

This finding, that doubling the dose extends duration by approximately a third a key feature of the curve: it is not linear. Beyond the threshold, increasing the dose produces progressively smaller in . There is a ceiling effect, and administering very high doses produces in terms of duration while increasing the risk of complications.

The relationship between dose and duration also varies by area. Factors that may the of action of botulinum toxin include the association of toxins with accompanying proteins, which can affect receptors, as well as the patient's emotional through gesticulation, toxin reconstitution, and the injection technique performed.

Areas of high muscular activity, the frown lines in a habitual frowner, the crow's feet of someone who smiles frequently and forcefully are subject to of compared to areas of lower activity. The dose required to achieve in high-activity areas is therefore greater than in ones.

The consequences of under-dosing in botulinum toxin practice are and well recognised by practitioners, even when they are rarely stated openly. A sub-therapeutic or dose a result that is partial, uneven, and short-lived. The patient that lines have incompletely, that movement persists in areas where it should have been adequately relaxed, and that the result begins to fade noticeably earlier than expected.

This poor result has a clinical cause, dose relative to the patient's muscle mass and threshold, and a commercial context. A clinic that prices botulinum toxin at the lower end of the market must, by financial necessity, keep costs proportionately low. Since the product cost is directly related to the amount used, a low-price treatment is structurally towards .

The less product than they need, experiences a disappointing result, and may be told at follow-up that they do not require a top-up because honouring the top-up at the original price would whatever margin the treatment was generating.

The top-up exists in responsible practice because the dose-response relationship makes it necessary. A first treatment should be calibrated conservatively. Particularly in a new patient whose muscle and response have not yet been with the of the result at two weeks and where clinically indicated. A clinic that declines to honour this is not simply on . It is failing to complete the episode that the treatment requires.

The dose-response relationship does not uniformly across . Individual in muscle mass, muscle strength, density, and metabolic rate all both the dose for clinical effect and the of that effect once achieved.

Primary to botulinum toxin refers to who show an innate insensitivity to the toxin upon initial exposure, without prior treatments or antibody development. Non-response or has become an increasingly significant concern, particularly since younger patients who are increasingly opting for aesthetic greater total toxin doses over their lifetime.

This individual is the argument against treatment templates. That is, fixed points at fixed doses identically to every patient. Such may have been developed and validated in relatively study populations, and may perform adequately in whose anatomy resembles that population.

However, they poorly in patients whose muscle anatomy, strength, or differ from that template. This is frequently the case in older patients, in with asymmetry, and in patients who have compensatory muscle activity in to the changes we have written about elsewhere in this blog.

A clinical assessment should ever botulinum toxin treatment. It should include, at minimum :

an evaluation of the resting and movement of the muscles,

an assessment of compensation patterns — particularly in the and around the eye

a judgement about the relative muscle mass being treated.

This assessment informs the dose and the . Without it, the is not treating the . They are a template of a and the results, as many have discovered, are correspondingly .

A consideration that is rarely discussed in aesthetic toxin practice, but that has long-term implications, is the relationship between dose and immunogenicity. This is the risk of developing neutralising antibodies that reduce or eliminate the clinical response to future .

Secondary is a in which toxin is at onset but becomes ineffective later. Factors to this include antigenicity, presentation, clinical practice, and lifestyle.

While the risk of clinically significant antibody at cosmetic doses is low, it is not zero and it is directly related to the total load delivered with each treatment and the of treatments. This is one of the for using the minimum effective dose rather than defaulting to higher doses as a strategy for extending duration: the long-term protection of the patient's immunological to treatment is a clinical consideration that more than it typically .

The advent of purer toxin formulations such as Bocouture (Xeomin), which contains no complexing was partly by the theoretical reduction in immunogenic stimulus compared to formulations containing accessory proteins. Whether this translates into a meaningful clinical in formation rates at doses remains debated, but the principle of minimising unnecessary protein load is sound.

The evidence supports a to botulinum toxin that is calibrated, initiated, and properly at follow-up.

The appropriate starting dose is determined by of the individual — their muscle mass, their movement patterns, their behaviours, and any history of previous treatment and . It is not determined by a price point or a template.

The follow-up appointment at two weeks is not . It is the second half of a that cannot be without it. The result is assessed, the brow and eye examined, and where it is both needed and safe. This is how responsible toxin practice works and the science is one of the why.

The views expressed in Clinical Perspectives are the Dr Forrester’s own and reflect his and experience of over 25 years in aesthetic medicine.

References

Hexsel D et al. Botulinum toxin: examining of effect in facial . DARE Database of Reviews. NCBI . 

Fagien S et al. Safety and of Effect of 40-Unit for the Treatment of Moderate to Severe Glabellar OnabotulinumtoxinAAbobotulinumtoxinAIncobotulinumtoxinAPrabotulinumtoxinALetibotulinumtoxinARimabotulinumtoxinBHyaluronic Acid FillersCalcium Hydroxylapatite FillersPoly-L-lactic Acid FillersPolymethylmethacrylate FillersAutologous Fat GraftingForehead Lines TreatmentGlabellar Frown Lines TreatmentCrow's Feet TreatmentBunny Lines TreatmentChemical Brow LiftLip FlipGummy Smile CorrectionMasseter ReductionJaw SlimmingDimpled Chin SmoothingCobblestone Chin SmoothingNefertiti Neck LiftMicro-BotoxMesotoxHyperhidrosis TreatmentChronic Migraine ReliefBruxism TreatmentTMJ TreatmentCervical Dystonia TreatmentNeck Spasm TreatmentBlepharospasm TreatmentLip AugmentationLip ContouringCheekbone EnhancementTear Trough FillersNasolabial Fold SofteningMarionette Line FillersLiquid RhinoplastyNon-Surgical Nose JobJawline ContouringJawline DefinitionChin AugmentationTemple VolumisingHand RejuvenationAcne Scar Subcision Filling. Aesthetic . 2024. 

J, García F. Controversies about toxin type A duration effect.  Medicine.2025;11(1). 

Feighelstein MEB. Duration of botulinum toxin effects: Determining factors and practical . PMFA Journal. December 2025. 

to Botulinum Toxin in . JMIR . 2025. 

Filler-Induced Vascular Occlusion

Why Botox Treatments Last Longer Over Time

6 Esher Park Avenue
Esher, Surrey KT10 9NP

Tel: ‬
Tel: ‭ ‬

© 2026
The Ltd
Company no.